Urothelial Carcinoma of the Bladder
📧 Sign up to get email alerts when something new happens for Urothelial Carcinoma of the Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating whether circulating tumor DNA in blood can guide the use of immunotherapy after surgical removal of urot…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study [Phase 3]
A Phase 3 trial (MAIN-CAV) is evaluating the addition of cabozantinib to the immunotherapy drug avelumab for metastatic urothelial cancer, w…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [Phase 1]
Phase 1 trial evaluating [225Ac]Ac-AKY-1189 for solid tumors is currently recruiting, including urothelial carcinoma of the bladder and trip…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating modern immunotherapy for non-muscle invasive bladder cancer (urothelial carcinoma of the bladder) in BCG…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
A clinical trial update focusing on tumor budding and T1 sub-staging in urothelial bladder cancer; recruitment is not yet started.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer [Phase 3]
Phase 3 clinical trial update evaluating eribulin plus standard chemotherapy versus standard chemotherapy alone for metastatic urothelial ca…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer [Phase 3]
Phase 3 trial status update for pembrolizumab after surgery in localized muscle-invasive bladder cancer and locally advanced urothelial carc…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer
This entry notes a clinical trial (NCT07511517) evaluating the BladMetrix urine test to monitor recurrence in non-muscle invasive bladder ca…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study [Phase 3]
A Phase 3 trial (ARCHER) compares shorter-duration radiation therapy plus standard chemotherapy to standard radiation therapy with chemother…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer [Phase 2]
A Phase 2 clinical trial evaluating preoperative immunotherapy combined with sacituzumab govitecan for muscle-invasive bladder cancer is cur…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer [Phase 1]
Phase 1 clinical trial evaluating IO102-IO103 in combination with pembrolizumab for high-risk non-muscle invasive bladder cancer that is unr…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This clinical trial update describes the use of a live tumor diagnostic platform to evaluate immune checkpoint inhibitor responses across mu…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer [Phase 3]
Relmada Therapeutics is evaluating NDV-01, a sustained-release gemcitabine-docetaxel formulation, in Phase 3 for non-muscle invasive bladder…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors [Phase 2]
This Phase 2 trial update evaluates pemetrexed response in metastatic urothelial bladder cancer and other solid tumors based on tumor gene a…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma [Phase 2]
Phase 2 trial evaluating immune checkpoint inhibitors with or without propranolol hydrochloride in urothelial carcinoma; the study is curren…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder [Phase 2]
Phase II multicenter study comparing chemotherapy alone versus chemotherapy plus durvalumab (MEDI4736) in patients with lymph node–positive …
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer [Phase 3]
This entry reports a Phase 3 trial of UGN-103 for low-grade, intermediate-risk non-muscle invasive bladder cancer and indicates the study is…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
Clinical trial update on Bladder CARE™, a non-invasive urine test designed to detect bladder cancer in inconclusive cases.
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB)
A Mayo Clinic-sponsored study evaluating ultrasound-guided core needle biopsy to stage urothelial carcinoma of the bladder is currently recr…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy [Phase 2]
Phase 2 trial evaluating futibatinib in combination with durvalumab prior to cystectomy for patients with muscle-invasive bladder cancer ine…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients [NA]
A clinical trial update describing Hyperthermic Intravesical Chemotherapy (HIVEC) for high-grade non-muscle invasive bladder cancer that is …
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy [NA]
Clinical trial entry from Johns Hopkins University recruiting to study home intravenous fluid infusion after radical cystectomy for bladder …
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is evaluating infusion of NY-ESO-1–specific TCR-engineered lymphocytes in patients with NY-ESO-1-expressing…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study [Phase 2]
This update describes an open-label, randomized Phase 2 trial evaluating toripalimab with or without sequential intravesical gemcitabine-mit…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy [Phase 2]
Phase 2 clinical trial evaluating a decision-support tool to select women for gynecologic-sparing radical cystectomy in urothelial carcinoma…